Coverage in The Australian

Interesting commentary by Rebecca Urban in The Australian this morning. A big thank you to the hundreds of people from the Australian biosciences industry who reached out in personal support over the past few weeks. I actually wish Chris Roberts every success. Notwithstanding my views on the product, if anyone should be able to fix the company’s corporate governance,…

Rhinomed : Long Tail, you can’t be serious…?

Guest Post : Peter Murphy I was taken aback by the (maybe a little tongue in cheek?) endorsement given to Rhinomed (ASX : RNO) by The Long Tail in a recent review. I also don’t think this company belongs in the “green” category, I believe it belongs in the deep red, maybe even magenta category. So…

ResMed – An Alternative Perspective

I wouldn’t normally comment on ResMed because I don’t consider it to be an “Australian” company any more, nor with its current multi-$Bn valuation is it in the “long tail” of the ASX either… But I was thinking a lot about ResMed over the weekend for basically two reasons. Firstly, I previously, with some degree…

Well played, Rhinomed, well played…

Rhinomed (ASX:RNO) is honestly the worst example of quasi-science and medical “devices” married with superb marketing. This is basically just another bit of plastic you can stick up your schnoz (and there are many), but it is a super-powered, whizz-bang, clinically proven, FDA-blessed nasal dilator, and that makes it truly special. The marketing angle around…